Adding elotuzumab to myeloma treatment decreases risk of disease progression
the ONA take:
The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced risk of disease progression or death by 30% in patients with relapsed or refractory multiple myeloma, according to a new study published online in the New England Journal of Medicine and presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, this week.
For the phase III ELOQUENT-2 trial, researchers randomly assigned 646 patients with relapsed or refractory multiple myeloma to receive lenalidomide plus dexamethasone with or without elotuzumab.
Results showed that after a median follow-up of 24.5 months, the 1-year progression-free survival rate was 68% in the elotuzumab group versus 57% in the control group. The 2-year progression-free survival rates were 41% and 27%, respectively. Researchers found that median progression-free survival was 19.4 months in the elotuzumab group compared with 14.9 months in the control group.
In regard to safety, the most common grade 3 or 4 adverse events in both groups were fatigue, lymphocytopenia, neutropenia, and pneumonia. In the elotuzumab group, 10% of patients experienced infusion-related reactions, of which the majority were grade 1 or 2.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|